Clexane in STEMI

Clexane (enoxaparin) is now licensed in the treatment of acute ST-segment Elevation Myocardial Infarction (STEMI). It may be given in patients who are to be medically managed or those who are undergoing subsequent percutaneous coronary intervention (PCI) in conjunction with thrombolytic drugs (fibrin or non-fibrin specific).

An initial dose of 30mg should be given as an intravenous bolus injection plus a 1mg/kg subcutaneous injection followed by 1mg/kg subcutaneously every 12 hours.

View Clexane drug record

Further information: Sanofi-aventis

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more